Floatz logo

Exendin 9-39

Obesity

Icahn School of Medicine at Mount SinaiPhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB

View all 50 →

Same molecule, other indications

Exendin 9-39 is also rated in:

Type 2 DiabetesDormant
D
Indicative ·
30 / 100
View asset →
morbid obesityDormant
D
Indicative ·
30 / 100
View asset →
dumping syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →